E.BrosseronF.FeinsteinD
By Application Analysis Type 2 Diabetes Management: This segment held the largest market share in 2024, driven by increasing investments in research, awareness programs, and combination therapies for glycemic control
Roxybond leverages Protegas SentryBond abuse-deterrent technology, which combines inactive excipients with active pharmaceutical ingredients to make the tablet more difficult to manipulate for misuse and abuse, even with physical manipulation or chemical extraction
No human dose is recommended by this wiki
Published human evidence includes topical applications over defined periods, diabetic-ulcer wound protocols, and a registered topical acute-wound trial, while there is no FDA-approved injectable GHK-Cu label that establishes a standard dose [2], [3], [7], [8]